br1015-1
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 16, 2021 (NCT05097794)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Angiotensin II receptorANTAGONIST
Angiotensin II receptor antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06744439 | Phase 1 | Jan 9, 2025 | Boryung Pharmaceutical Company |
| NCT06744062 | Phase 1 | Jan 5, 2025 | Boryung Pharmaceutical Company |
| NCT06744426 | Phase 1 | Jan 4, 2025 | Boryung Pharmaceutical Company |
| NCT06744127 | Phase 1 | Jan 3, 2025 | Boryung Pharmaceutical Company |
| NCT06008015 | Phase 1 | Sep 4, 2023 | Boryung Pharmaceutical Company |
| NCT06008028 | Phase 1 | Aug 10, 2023 | Boryung Pharmaceutical Company |
| NCT05097794 | Phase 1 | Aug 16, 2021 | Boryung Pharmaceutical Company, Cha Medical University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Company | For profit | 7 | 7 | 1 | 2021 |
| Cha Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1